How Robins was paid
$9.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Chad RobinsChief Executive Officer and Chairman | $698,258 | $7,675,100 | — | $703,380 | $4,952 | $9,081,690 |
| Kyle PiskelChief Financial Officer | $399,950 | $2,702,500 | — | $203,300 | $4,979 | $3,310,729 |
| Susan BobulskyChief Commercial Officer, MRD | $435,750 | $1,883,990 | $997,325 | $226,013 | $4,480 | $3,547,558 |
| Harlan Robins, PhDChief Scientific Officer | $558,653 | $7,675,100 | — | $270,823 | $4,999 | $8,509,575 |
| Julie RubinsteinPresident and Chief Operating Officer | $542,383 | $3,783,500 | — | $273,180 | $4,932 | $4,603,995 |
What changed and why
- $9.1MChad Robins received a total compensation of $9,081,690 in 2025, representing an increase from $4,973,301 in 2024.
- Adaptive Biotechnologies adjusted its pay philosophy to generally target the market median for executive compensation elements.
- The company diligently managed burn rate by pursuing a flat-share grant approach for the executive team.
- Performance stock units were granted to key executive officers with a three-year performance period.
- Corporate performance objectives captured achieving quarterly adjusted EBITDA profitability in the MRD business in 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.